18 Years - VISION and IVY Networks, September 2023-January 2024. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Mortality risk after COVID-19 vaccination: a self-controlled case series study. 

Vaccine. 2024

Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 

Lancet (London, England). 2024

Tinnitus after COVID-19 vaccination: findings from the vaccine adverse event reporting system and the vaccine safety datalink. 

American Journal of Otolaryngology. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

A broad assessment of COVID-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. 

Vaccine. 2023

A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. 

Vaccine. 2023

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 

Lancet Reg Health Am. 2023

Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. 

Journal of Infectious Diseases. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. 

Vaccine. 2023

Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink. 

Vaccine. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 

JAMA network open. 2022

Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. 

JAMA network open. 2022

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 

Vaccine. 2022

Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 

Pediatrics. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 

BMJ (Clinical research ed.). 2022

COVID-19 vaccination coverage among insured persons aged ≥16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 

New England Journal of Medicine. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Surveillance for adverse events after COVID-19 mRNA vaccination. 

JAMA. 2021

Safety of measles-containing vaccines in 1-year-old children. 

Pediatrics. 2015

Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. 

JAMA pediatrics. 2013

Guillain-Barre syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. 

PloS One. 2013

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. 

Diabetes care. 2013

Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling. 

Journal of Clinical Epidemiology. 2013

Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes. 

Pharmacoepidemiology and Drug Safety. 2012

Measles-containing vaccines and febrile seizures in children age 4 to 6 years. 

Pediatrics. 2012

Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. 

Journal of Internal Medicine. 2012

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. 

JAMA. 2011

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. 

American Journal of Preventive Medicine. 2011

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. 

Pediatrics. 2010

Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. 

American Journal of Epidemiology. 2010

Impact of specific glucose-control strategies on microvascular outcomes in 58,000 adults with type 2 diabetes [poster]

2013

Application of dynamic marginal structural modeling to compare glycemic control strategies that are more versus less aggressive in type 2 diabetes patients [presentation], AHRQ 3rd Symposium on Comparative Effectiveness Research Methods

Comparison of more vs less aggressive glycemic control strategies in type 2 diabetes patients. Application of dynamic marginal structural modeling [presentation], AHRQ (Agency for Healthcare Research and Quality) Methods Symposium